CPS Technologies to Report 2025 Financial Results on March 3

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

CPS Technologies will report 2025 financial results on March 3, 2026 via investor conference call with CEO and CFO discussing annual performance.

CPS Technologies to Report 2025 Financial Results on March 3

CPS Technologies Corp. (Nasdaq: CPSH) has scheduled an investor conference call for March 3, 2026 at 9:00 a.m. Eastern Time to present its financial performance for the fiscal year ended December 27, 2025. The company's leadership team, including President and Chief Executive Officer Brian Mackey and Chief Financial Officer Chuck Griffith, will review the year-end results and address investor inquiries during the session.

The conference call represents a standard opportunity for the semiconductor materials company to communicate directly with shareholders and analysts regarding its annual operating performance and strategic outlook. Investors and market participants can typically access such calls through the company's investor relations channels.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 25

Related Coverage

GlobeNewswire Inc.

Sika AG Shareholders Approve Board, Boost Dividend to CHF 3.70 Per Share

Sika AG shareholders approved CHF 3.70 dividend and board re-election at 2026 AGM, with company reporting CHF 11.20B sales and 33,700 employees globally.

SXYAY
GlobeNewswire Inc.

17EdTech Posts Narrower Loss Despite Revenue Decline as AI Product Gains Traction

17EdTech reports Q4 revenue growth of 6.4% YoY and significant margin expansion, though full-year revenues declined 44% due to business model shift. New AI product 'Yiqi Aixue' shows strong pre-sale demand.

YQ
The Motley Fool

Slide Insurance Posts $444M Profit on Strong Revenue Growth; Insider Trims Position

Slide Insurance reported $444M net income and $1.16B revenue, up 36% YoY. Director sold $1M in shares via pre-arranged plan while maintaining substantial stake.

SLDE
GlobeNewswire Inc.

IMUNON Sets March 31 Call to Detail 2025 Results, OVATION 3 Trial Progress

$IMNN to discuss 2025 results and OVATION 3 Phase 3 trial progress for IMNN-001 ovarian cancer immunotherapy on March 31, 2026.

IMNN
GlobeNewswire Inc.

Inventiva to Report 2025 Results as MASH Drug Candidate Advances

Inventiva will release 2025 financial results March 30, 2026, while advancing lanifibranor in Phase 3 MASH trials.

IVA
GlobeNewswire Inc.

Inventiva to Report 2025 Results as MASH Drug Candidate Advances in Phase 3

Inventiva to release 2025 financial results March 30, 2026, as its lanifibranor MASH drug advances through Phase 3 clinical trials.

IVA